HIV DART: Frontiers in Drug Development for Antiretroviral Therapies

描述(由申请人提供)： 治疗的进步使艾滋病毒从一种致命的疾病--在联合治疗出现之前对感染者来说是现实--转变为一种长期的慢性病。正如预期的那样，需要终身治疗的人数正在增加，仍然需要副作用更少的改进治疗方法，以及有朝一日可能根除这种病毒的方法。传染病保健工作者和研究人员必须跟上新药发展的步伐，以促进艾滋病毒新的有效疗法的开发，特别是在第三世界国家。HIV DART：抗逆转录病毒治疗药物开发的前沿是一项两年一度的会议，旨在引起医生、临床医生、护士、科学家和临床研究人员对艾滋病毒、(与乙肝病毒/丙型肝炎病毒)混合感染和逆转录病毒学领域的兴趣。 具体目标：1)将临床医生、护士、研究人员和基础科学家聚集在一起，促进对抗逆转录病毒研究中正在进行的药物开发过程的了解；2)融合生物学、化学、药理学和临床研究领域，使科学界更好地了解艾滋病毒感染疗法当前和未来的挑战；以及3)通过学员奖学金补充和加强对各国代表性不足的科学家、年轻研究生、护士和/或博士后研究员的培训。 教育目标：1)了解病毒靶点在药物发现和开发过程中的作用；2)确定逆转录病毒的新型治疗剂和病毒靶点；3)制定改进的战略，以减少或消除抗药性和毒性；4)了解宿主和病毒在根除艾滋病毒方面的持久性；5)开发杀微生物剂和其他预防方法；6)了解肝炎合并感染对艾滋病毒感染者管理的后果；7)提供与临床药物开发相适应的新型免疫学方法的见解；8)制定有针对性的方法，以改善抗逆转录病毒药物的药理作用；以及9)了解儿科和老龄人口中的艾滋病毒治疗。 设计与方法： HIV DART计划将由一个国际公认的计划委员会设计，并在有利于来自全球的与会者的地点进行为期3.5天的活动。它将包括口头和海报形式的科学演示文稿。继续医学教育认证委员会(ACCME)认可的项目将为代表和教职员工之间的正式和非正式互动提供充足的时间。HIV DART通常发生在美国和美洲。相关性：HIV DART：抗逆转录病毒疗法药物开发的前沿是一个国际两年一次的会议，为包括第三世界国家在内的世界各地的传染病保健工作者和研究人员提供一个论坛，以了解艾滋病毒新的有效疗法的新发展。HIV DART还鼓励年轻科学家参与，向那些有被接受的陈述的人提供奖学金。HIV DART为医生提供经认可的继续医学教育培训，确保对全世界艾滋病毒的治疗产生持久和积极的公共卫生影响。

DESCRIPTION (provided by applicant): Advances in treatment have transformed HIV from being a fatal disease, which was the reality for infected individuals before the advent of combination treatment, into a long-term chronic condition. As expected, the number of individuals requiring life-long therapy is increasing and the need for improved therapies with fewer side effects are still needed, as well as approaches that may one day eradicate this virus. It is critical for infectious disease healthcare workers and researchers to keep abreast of new drug developments to facilitate the development of novel and potent therapies for HIV, especially in third world countries. HIV DART: Frontiers in Drug Development for Antiretroviral Therapy is a biennial conference to interest physicians, clinicians, nurses, scientists and clinical researchers in the HIV, co-infection (with HBV/HCV), and retrovirology arenas. Specific Aims: 1) Assemble clinicians, nurses, researchers and basic scientists together to advance knowledge of the ongoing drug development processes in antiretroviral research; 2) Blend the areas of biology, chemistry, pharmacology and clinical research to provide the scientific community an increased understanding of the current and future challenges in therapeutics for HIV infection; and 3) Supplement and enhance the training of underrepresented scientists from various countries, young graduate students, nurses, and/or post-doctoral fellows through attendee scholarships. Educational Objectives: 1) Understand the role of viral targets in the drug discovery and development process; 2) Identify novel therapeutic agents and viral targets for retroviruses; 3) Develop improved strategies to reduce or eliminate drug-resistance and toxicity; 4) Understand reservoirs and viral persistence towards HIV eradication; 5) Develop microbicides and other preventative approaches; 6) Understand the consequences of hepatitis co-infection on the management of HIV-infected individuals; 7) Provide insights on novel immunological approaches compatible with clinical drug development; 8) Develop targeted approaches to improve the pharmacology of antiretroviral agents; and 9) Understand HIV therapy in pediatrics and the aging population. Design & Methods: The HIV DART program will be designed by an internationally-recognized Program Committee, and conducted over 3.5 days in locations conducive to attendance from around the globe. It will include scientific presentations in both oral and poster presentation formats. The Accreditation Council for Continuing Medical Education (ACCME) accredited program will provide ample time for formal and informal interactions between delegates and faculty. HIV DART usually takes place in the United States and the Americas. Relevance: HIV DART: Frontiers in Drug Development for Antiretroviral Therapies is an international biennial conference that provides a forum for infectious disease healthcare workers and researchers from around the globe, including third world countries, to learn about new developments in novel and potent therapies for HIV. HIV DART also encourages young scientists to participate by providing scholarships to those that have an accepted presentation. HIV DART provides accredited Continuing Medical Education training for physicians, ensuring a lasting and positive public health impact on treatment of HIV throughout the world.